Significantly heightened bleeding risk with Bayer/J&J's Xarelto suggests a difficult approval route for the oral anticoagulant in acute coronary syndrome.
Continue reading "Coming In Monday's "The Pink Sheet" DAILY - UK's NICE Rejects Sanofi's Jevtana" »
Vanderbilt University's Center for Neuroscience Drug Discovery continues to make progress on the business development front. In recent days, it has delivered preclinical compounds for fragile X disease to Seaside Therapeutics, selected three mGlu4 modulators for continued development in Parkinson's disease under a collaboration with the Michael J. Fox Foundation, and licensed a set of glycine transporter one inhibitors to Karuna Pharmaceuticals for development in schizophrenia.
Continue reading "Coming In Friday's "The Pink Sheet" DAILY" »
Onyx files carfilzomib NDA in relapsed refractory myeloma, requests priority review based on one single-arm Phase II study.
Continue reading "Coming In Thursday's "The Pink Sheet" DAILY - Onyx Submits Carfilzomib NDA" »
Medicare cost-sharing incentives would drive higher generic drug use by low-income enrollees in Part D, a MedPAC staff analysis of claims suggests.
Continue reading "Coming In Wednesday's "The Pink Sheet" DAILY" »
